Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis & T-cells
Public ClinicalTrials.gov record NCT01351025. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Pilot Study Evaluating the Effect of Atorvastatin on Biomarkers of Inflammation, Coagulopathy, Angiogenesis, and T-lymphocyte Activation in HIV-1 Infected Individuals With Suppressed HIV-1 RNA and LDL Cholesterol < 130 mg/dL
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
ACTG A5275 was a prospective, double-blind, randomized, placebo-controlled cross-over design pilot study evaluating the effect of atorvastatin on biomarkers of inflammation, coagulopathy, angiogenesis, and T-lymphocyte activation in HIV-1 infected individuals with suppressed HIV-1 RNA on stable protease inhibitor based antiretroviral therapy with fasting LDL cholesterol \< 130 mg/dL. Atorvastatin is a drug approved by the Food and Drug Administration (FDA) for treating high cholesterol. Atorvastatin has also been able to lower the level of inflammation blood tests in certain other diseases but has not been studied for this purpose in people who have HIV. The main goal of this experimental study is to see how taking atorvastatin affects inflammation blood tests in people infected with HIV who do not need to take medicine for high cholesterol. In addition to observing the effects of atorvastatin on the level of inflammation measured in the blood, this study evaluated if atorvastatin is safe for people with HIV who are also taking medication for HIV.
Study identification
- NCT ID
- NCT01351025
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 98 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 14, 2011 (Actual)
- Primary completion
- May 2014 (Actual)
- Completion
- May 2014 (Actual)
- Last update posted
- Aug 3, 2021
2011 – 2014
United States locations
- U.S. sites
- 30
- U.S. states
- 16
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 31788 Alabama CRS | Birmingham | Alabama | 35294 | — |
| UCLA CARE Center CRS (601) | Los Angeles | California | 90095 | — |
| Ucsd, Avrc Crs (701) | San Diego | California | 92103 | — |
| Harbor-UCLA Med. Ctr. CRS (603) | Torrance | California | 90502 | — |
| University of Colorado Hospital CRS (6101) | Aurora | Colorado | 80045 | — |
| Georgetown University CRS (GU CRS) (1008) | Washington D.C. | District of Columbia | 20007 | — |
| Northwestern University CRS (2701) | Chicago | Illinois | 60611 | — |
| Massachusetts General Hospital ACTG CRS (101) | Boston | Massachusetts | 02114 | — |
| Brigham and Women's Hosp. ACTG CRS (107) | Boston | Massachusetts | 02115 | — |
| Beth Israel Deaconess Med. Ctr., ACTG CRS (103) | Boston | Massachusetts | 02215 | — |
| Wayne State Univ. CRS (31478) | Detroit | Michigan | 48201 | — |
| Henry Ford Hosp. CRS (31472) | Detroit | Michigan | 48202 | — |
| Washington U CRS (2101) | St Louis | Missouri | 63110 | — |
| Cooper Univ. Hosp. CRS (31476) | Camden | New Jersey | 08103 | — |
| New Jersey Medical School-Adult Clinical Research Ctr. CRS (31486) | Newark | New Jersey | 07103 | — |
| Cornell CRS (7804) | New York | New York | 10011 | — |
| NY Univ. HIV/AIDS CRS (401) | New York | New York | 10016 | — |
| AIDS Care CRS (1101) | Rochester | New York | 14642 | — |
| University of Rochester Adult HIV Therapeutic Strategies Network CRS (31787) | Rochester | New York | 14642 | — |
| Unc Aids Crs (3201) | Chapel Hill | North Carolina | 27516 | — |
| Duke Univ. Med. Ctr. Adult CRS (1601) | Durham | North Carolina | 27710 | — |
| Univ. of Cincinnati CRS (2401) | Cincinnati | Ohio | 45267 | — |
| Case CRS (2501) | Cleveland | Ohio | 44106 | — |
| Metro Health CRS (2503) | Cleveland | Ohio | 44109 | — |
| The Ohio State Univ. AIDS CRS (2301) | Columbus | Ohio | 43210 | — |
| Hosp. of the Univ. of Pennsylvania CRS (6201) | Philadelphia | Pennsylvania | 19104 | — |
| Pitt CRS (1001) | Pittsburgh | Pennsylvania | 15213 | — |
| Houston AIDS Research Team CRS (31473) | Houston | Texas | 77030 | — |
| Virginia Commonwealth Univ. Medical Ctr. CRS (31475) | Richmond | Virginia | 23219 | — |
| University of Washington AIDS CRS (1401) | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01351025, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 3, 2021 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01351025 live on ClinicalTrials.gov.